Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates
Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.
MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?
Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.
How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.
How LEON’s FR-JET modular mixer achieved stable high-concentration mRNA-LNPs in a peer-reviewed study
Find out how a peer-reviewed study shows LEON’s FR-JET modular mixer enabling stable high-concentration mRNA-LNPs with enhanced in vivo activity.
Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME
Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study […]
Why Biofrontera Inc.’s dual database locks mark a critical step toward validated clinical and regulatory data
Biofrontera Inc. has confirmed that databases for two of its clinical studies have been formally locked, a procedural milestone that signals the completion of data collection and validation and the transition into final statistical analysis. Although database locks rarely attract the same level of attention as topline efficacy readouts, they represent one of the most […]